PL1842920T3 - Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K - Google Patents

Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K

Info

Publication number
PL1842920T3
PL1842920T3 PL07109353T PL07109353T PL1842920T3 PL 1842920 T3 PL1842920 T3 PL 1842920T3 PL 07109353 T PL07109353 T PL 07109353T PL 07109353 T PL07109353 T PL 07109353T PL 1842920 T3 PL1842920 T3 PL 1842920T3
Authority
PL
Poland
Prior art keywords
vitamin
dependent protein
reductase
productivity
improve
Prior art date
Application number
PL07109353T
Other languages
English (en)
Other versions
PL1842920T5 (pl
Inventor
Darrel Stafford
Tao Li
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34393028&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1842920(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of PL1842920T3 publication Critical patent/PL1842920T3/pl
Publication of PL1842920T5 publication Critical patent/PL1842920T5/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
PL07109353T 2003-09-23 2004-09-23 Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K PL1842920T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50552703P 2003-09-23 2003-09-23
EP04789039.7A EP1670947B1 (en) 2003-09-23 2004-09-23 Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
EP07109353.8A EP1842920B2 (en) 2003-09-23 2004-09-23 Cells coexpressing vitamin K reductase and vitamin K dependent protein and use thereof to improve the productivity of said vitamin K dependent protein

Publications (2)

Publication Number Publication Date
PL1842920T3 true PL1842920T3 (pl) 2010-06-30
PL1842920T5 PL1842920T5 (pl) 2018-04-30

Family

ID=34393028

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07109353T PL1842920T5 (pl) 2003-09-23 2004-09-23 Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K

Country Status (13)

Country Link
US (6) US7687233B2 (pl)
EP (4) EP2336360A1 (pl)
JP (4) JP2007506433A (pl)
AT (1) ATE455174T1 (pl)
AU (2) AU2004275828B2 (pl)
CA (1) CA2539434C (pl)
DE (1) DE602004025157D1 (pl)
DK (2) DK1842920T4 (pl)
ES (2) ES2339710T5 (pl)
HK (1) HK1093223A1 (pl)
PL (1) PL1842920T5 (pl)
PT (1) PT2380985E (pl)
WO (1) WO2005030039A2 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539434C (en) * 2003-09-23 2014-03-18 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
PL2189523T3 (pl) * 2003-10-14 2012-05-31 Baxalta Inc Polipeptyd przekształcający epoksyd witaminy K VKORC1, obiekt działania leczniczego kumaryny i jej pochodnych
WO2006012902A2 (en) * 2004-08-02 2006-02-09 Novozymes A/S Creation of diversity in polypeptides
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
EP1809767B1 (en) * 2004-10-18 2011-09-07 University of Washington Methods and compositions for predicting response to warfarin
WO2006069339A2 (en) * 2004-12-21 2006-06-29 Academia Sinica Genetic variants of vkorci predicting warfarin sensitivity
EP2295547B1 (en) * 2005-02-28 2017-09-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US7989193B2 (en) 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
US8500720B2 (en) * 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
PT1969127E (pt) 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
WO2007143617A1 (en) * 2006-06-02 2007-12-13 Academia Sinica Warfarin dosage prediction
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
KR20110016440A (ko) 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
WO2010045381A2 (en) * 2008-10-15 2010-04-22 President And Fellows Of Harvard College Antimicrobial agents that target bacterial vkor
AU2010269072C9 (en) 2009-07-10 2014-09-18 Csl Limited Method of increasing the expression yield of vitamin K-dependent proteins
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS
JP2012139232A (ja) * 2012-03-15 2012-07-26 Univ Of North Carolina At Chapel Hill 活性ビタミンk依存性タンパク質を生産するための方法及び組成物
JP2014221048A (ja) * 2014-06-16 2014-11-27 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンk依存性タンパク質を生産するための方法及び組成物
BR102015012334A2 (pt) * 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3485810T2 (de) 1983-05-27 1992-12-10 Texas A & M University Syst Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4736866A (en) * 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
WO1986006408A1 (en) 1985-04-22 1986-11-06 Genetics Institute, Inc. HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
JPH01502080A (ja) 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンk依存性蛋白質のガンマカルボキシル化の増強
JPH03501921A (ja) 1987-05-18 1991-05-09 インテグレイテッド・ジェネティクス・インク 改良タンパク質分子、並びにその製造及び活性化方法
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
WO1991001372A1 (en) 1989-07-17 1991-02-07 New England Medical Center Hospitals, Inc. VITAMIN K-DEPENDENT η-CARBOXYLASE
WO1992001795A1 (en) 1990-07-23 1992-02-06 Zymogenetics, Inc. Gamma-carboxylase and methods of use
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
ES2109336T3 (es) 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
US5965789A (en) 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
US5698765A (en) * 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) * 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) * 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) * 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−1遺伝子の機能が欠損したマウス
US5547835A (en) * 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5605798A (en) * 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
GB2303853B (en) 1994-06-16 1998-12-23 Us Health Variant alleles in cytochrome P450 expressing enzymes involved in metabolic processes
ZA965853B (en) * 1995-07-13 1998-01-12 Du Pont Merck Pharma Asymmetric synthesis of r and s warfarin and its analogs.
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
WO1999033983A1 (en) 1997-12-24 1999-07-08 Immunex Corporation V201 dna and polypeptides
US5896337A (en) 1998-02-23 1999-04-20 Micron Technology, Inc. Circuits and methods for multi-level data through a single input/ouput pin
WO2000003015A2 (en) * 1998-07-10 2000-01-20 Incyte Pharmaceuticals, Inc. Human transport protein homologs
EP1048054B1 (en) * 1998-11-18 2003-09-24 Koninklijke Philips Electronics N.V. Luminescent material
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US6492115B1 (en) * 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
WO2002029045A2 (en) 2000-10-02 2002-04-11 Novo Nordisk A/S Method for the production of vitamin k-dependent proteins
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
CA2441832A1 (en) * 2001-03-21 2002-12-27 Human Genome Sciences, Inc. Human secreted proteins
CA2539434C (en) 2003-09-23 2014-03-18 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
PL2189523T3 (pl) * 2003-10-14 2012-05-31 Baxalta Inc Polipeptyd przekształcający epoksyd witaminy K VKORC1, obiekt działania leczniczego kumaryny i jej pochodnych
EP1809767B1 (en) 2004-10-18 2011-09-07 University of Washington Methods and compositions for predicting response to warfarin
US7445896B2 (en) * 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006069339A2 (en) * 2004-12-21 2006-06-29 Academia Sinica Genetic variants of vkorci predicting warfarin sensitivity
WO2006067116A1 (en) 2004-12-21 2006-06-29 Novo Nordisk Health Care Ag Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
EP2295547B1 (en) * 2005-02-28 2017-09-20 Baxalta GmbH Recombinant co-expression of vitamin K epoxide reductase subunit 1 to improve vitamin K dependant protein expression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US7989193B2 (en) 2005-04-13 2011-08-02 Medimmune Limited Compositions and methods for producing gamma-carboxylated proteins
ATE486128T1 (de) 2005-12-02 2010-11-15 Univ Wake Forest Health Sciences Zusammensetzungen und verfahren zur erhöhung der produktion rekombinanter gamma-carboxylierter proteine
PT1969127E (pt) 2005-12-21 2014-09-23 Univ North Carolina Processo de produção de proteínas dependentes da vitamina k biologicamente activos por métodos recombinantes
WO2007143617A1 (en) 2006-06-02 2007-12-13 Academia Sinica Warfarin dosage prediction
JP2009005240A (ja) * 2007-06-25 2009-01-08 Nec Tokin Corp 無線ネットワークシステムおよび無線ネットワーク通信方法

Also Published As

Publication number Publication date
DK1842920T3 (da) 2010-05-03
JP2007506433A (ja) 2007-03-22
DK2380985T3 (en) 2014-03-17
AU2004275828B2 (en) 2010-04-29
CA2539434C (en) 2014-03-18
EP2380985B1 (en) 2014-01-01
US20110124000A1 (en) 2011-05-26
EP1670947A4 (en) 2008-11-05
WO2005030039A3 (en) 2005-07-21
DE602004025157D1 (de) 2010-03-04
EP1842920A1 (en) 2007-10-10
EP1842920B1 (en) 2010-01-13
AU2004275828A1 (en) 2005-04-07
WO2005030039A2 (en) 2005-04-07
JP2015180205A (ja) 2015-10-15
US20060240440A1 (en) 2006-10-26
JP2010268803A (ja) 2010-12-02
US20070190614A1 (en) 2007-08-16
US8426128B2 (en) 2013-04-23
JP5840539B2 (ja) 2016-01-06
JP2012161315A (ja) 2012-08-30
EP2336360A1 (en) 2011-06-22
ES2339710T3 (es) 2010-05-24
JP5094920B2 (ja) 2012-12-12
ATE455174T1 (de) 2010-01-15
AU2010203318A1 (en) 2010-08-12
US20090215061A1 (en) 2009-08-27
US20090215045A1 (en) 2009-08-27
US7524665B2 (en) 2009-04-28
AU2010203318B2 (en) 2012-07-12
US7858318B2 (en) 2010-12-28
EP1842920B2 (en) 2017-06-21
EP1670947B1 (en) 2015-04-01
HK1093223A1 (en) 2007-02-23
ES2339710T5 (es) 2017-10-05
US20070009950A1 (en) 2007-01-11
PT2380985E (pt) 2014-03-26
DK1842920T4 (da) 2017-08-21
US7482141B2 (en) 2009-01-27
US8097410B2 (en) 2012-01-17
PL1842920T5 (pl) 2018-04-30
US7687233B2 (en) 2010-03-30
EP2380985A1 (en) 2011-10-26
ES2453895T3 (es) 2014-04-08
EP1670947A2 (en) 2006-06-21
CA2539434A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
PL1842920T3 (pl) Komórki koekspresjonujące reduktazę witaminy K i białko zależne od witaminy K oraz ich zastosowanie do poprawienia wydajności wytwarzania tego białka zależnego od witaminy K
AU2003241311A1 (en) Simple catalytic dna biosensors for ions based on color changes
TW200720441A (en) New labelling strategies for the sensitive detection of analytes
ATE330038T1 (de) Nukleinsäure-biosensor
WO2004058990A3 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
MXPA05014238A (es) Metodo para la deteccion de citosina alquilada en adn.
WO2004053105A3 (en) Direct SNP detection with unamplified DNA
SI1730315T1 (sl) Polimorfizmi v genu NOD2/CARD15
EP1741793A4 (en) HYBRIDIZATION PROCESS
WO2006039673A3 (en) Primers, methods and kits for amplifying or detecting human leukocyte antigen alleles
DE60228089D1 (de) Nukleinsäureamplifikation mit duplexzwischenprodukten
AU2003257177A1 (en) Improved compositions for in vitro amplification of nucleic acids
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2004000995A3 (en) Methods, probes, and accessory molecules for detecting single nucleotide polymorphisms
ATE443261T1 (de) Scintillation proximity assay
WO2004009843A3 (de) Nachweis von mikroorganismen
EP1598431A4 (en) PROCESS FOR DETECTING CHLAMYDIA TRACHOMATIS AND KIT THEREFOR
WO2005024045A3 (en) Primers for use in detecting beta-lactamases
WO2003093501A3 (en) Ssh based methods for identifying and isolating unique nucleic acid sequences
WO2004029299A3 (de) Verfahren zum nachweis und zur differenzierung von bakterien
DE60208299D1 (de) Detektion von amplifizierten Genprodukten zur Gendetektion und Reagenzkit
AU2003285461A1 (en) Multienzymatic conductimetric or potentiometric biosensor with unicellular algae, detection method using same
WO2003018833A3 (en) 3-hydroxymethylglutaryl coenzyme a reductase and diagnosis and prognostication of dementia
ATE542919T1 (de) Dna-seqeunzen zur detektion und unterscheidung von pathogenen e.coli-stämmen
WO2004020975A3 (en) Method for detecting microorganisms using pcr amplicons and microsphere agglutination